Resultados da busca - Mashael Alahmadi
- Mostrando 1 - 2 resultados de 2
-
1
Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia por Yaseen M. Arabi, Ali H. Hajeer, Thomas Luke, Kanakatte Raviprakash, Hanan H. Balkhy, Sameera Al Johani, Abdulaziz Al‐Dawood, Saad Al-Qahtani, Awad Al‐Omari, Fahad Al-Hameed, Frederick G. Hayden, Robert Fowler, Abderrezak Bouchama, Nahoko Shindo, Khalid S. Al-Khairy, Gail Carson, Yusri Taha, Musharaf Sadat, Mashael Alahmadi
Publicado em 2016Artigo -
2
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial por Mohammad Bosaeed, Hanan H. Balkhy, Sultan Almaziad, Haya A. Aljami, Hind Alhatmi, Hala Alanazi, Mashael Alahmadi, Ayah Jawhary, Mohammed W. Alenazi, Abdulrahman Almasoud, Rawan Alanazi, Mustapha Bittaye, Jeremy Aboagye, Nahla Awadh Albaalharith, Sarah Batawi, Pedro M. Folegatti, Fernando Ramos Lopez, Katie Ewer, Khalid Almoaikel, Majed Al-Jeraisy, Adel Alothman, Sarah C. Gilbert, Naif Khalaf Alharbi
Publicado em 2021Artigo
Ferramentas de busca:
Assuntos relacionados
Immunology
Internal medicine
Medicine
2019-20 coronavirus outbreak
Adverse effect
Antigen
Clinical trial
Convalescence
Convalescent plasma
Coronavirus disease 2019 (COVID-19)
Disease
Immune system
Immunogenicity
Immunotherapy
Infectious disease (medical specialty)
Outbreak
Randomized controlled trial
Reactogenicity
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Surgery
Tolerability
Vaccination
Virology